Validating ROS1 rearrangements as a therapeutic target in non-small-cell lung cancer

Journal of Clinical Oncology

Volumn 33, Issue 9, 2015, Pages 972-974

  Solomon, Benjamin ^a  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CRIZOTINIB; FIBROBLAST GROWTH FACTOR RECEPTOR 1; FIBROBLAST GROWTH FACTOR RECEPTOR 3; ONCOPROTEIN; PROTEIN TYROSINE KINASE; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE; ROS1 PROTEIN, HUMAN;

AUSTRALIA; CANCER SURVIVAL; CANCER THERAPY; EDITORIAL; EUROPE; FOLLOW UP; GENE; GENE FUSION; GENE MUTATION; GENE REARRANGEMENT; HUMAN; KOREA; NON SMALL CELL LUNG CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POTENTIAL DIFFERENCE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; ROS1 GENE; SAMPLE SIZE; SELECTION BIAS; TREATMENT RESPONSE; UNITED STATES; ADENOCARCINOMA; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; GENETICS; LUNG NEOPLASMS; MALE;

ADENOCARCINOMA; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; GENE REARRANGEMENT; HUMANS; LUNG NEOPLASMS; MALE; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS; PYRAZOLES; PYRIDINES;

EID: 84927130123     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.59.8334     Document Type: Editorial

References (35)

1. Shaw AT, Hsu PP, Awad MM, et al: Tyrosine kinase gene rearrangements in epithelial malignancies. Nat Rev Cancer 13:772-787, 2013
2. Soda M, Choi YL, Enomoto M, et al: Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448:561-566, 2007
3. Rikova K, Guo A, Zeng Q, et al: Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 131:1190-1203, 2007
4. Shaw AT, Kim DW, Nakagawa K, et al: Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 368:2385-2394, 2013
5. Solomon BJ, Mok T, Kim DW, et al: First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med 371:2167-2177, 2014
6. Mazières J, Zalcman G, Crinò L, et al: Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: Results from the EUROS1 cohort. J Clin Oncol 33:992-999, 2015
7. Birchmeier C, Sharma S, Wigler M: Expression and rearrangement of the ROS1 gene in human glioblastoma cells. Proc Natl Acad Sci U S A 84:9270-9274, 1987
8. Peraldo Neia C, Cavalloni G, Balsamo A, et al: Screening for the FIG-ROS1 fusion in biliary tract carcinomas by nested PCR. Genes Chromosomes Cancer 53:1033-1040, 2014
9. Liu P,WuY, Sun L, et al: ROS kinase fusions are not common in Chinese patients with cholangiocarcinoma. Nan Fang Yi Ke Da Xue Xue Bao 33:474-478, 2013
10. Gu TL, Deng X, Huang F, et al: Survey of tyrosine kinase signaling reveals ROS kinase fusions in human cholangiocarcinoma. PloS One 6:e15640, 2011
11. Birch AH, Arcand SL, Oros KK, et al: Chromosome 3 anomalies investigated by genome wide SNP analysis of benign, low malignant potential and low grade ovarian serous tumours. PloS One 6:e28250, 2011
12. Lee J, Lee SE, Kang SY, et al: Identification of ROS1 rearrangement in gastric adenocarcinoma. Cancer 119:1627-1635, 2013
13. Aisner DL, Nguyen TT, Paskulin DD, et al: ROS1 and ALK fusions in colorectal cancer, with evidence of intratumoral heterogeneity for molecular drivers. Mol Cancer Res 12:111-118, 2014
14. Gainor JF, Shaw AT: Novel targets in non-small cell lung cancer: ROS1 and RET fusions. Oncologist 18:865-875, 2013
15. Chin LP, Soo RA, Soong R, et al: Targeting ROS1 with anaplastic lymphoma kinase inhibitors: A promising therapeutic strategy for a newly defined molecular subset of non-small-cell lung cancer. J Thorac Oncol 7:1625-1630, 2012
16. Bergethon K, Shaw AT, Ou SH, et al: ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol 30:863-870, 2012
17. Rimkunas VM, Crosby KE, Li D, et al: Analysis of receptor tyrosine kinase ROS1-positive tumors in non-small cell lung cancer: Identification of a FIG-ROS1 fusion. Clin Cancer Res 18:4449-4457, 2012
18. Davies KD, Le AT, Theodoro MF, et al: Identifying and targeting ROS1 gene fusions in non-small cell lung cancer. Clin Cancer Res 18:4570-4579, 2012
19. Yasuda H, de Figueiredo-Pontes LL, Kobayashi S, et al: Preclinical rationale for use of the clinically available multitargeted tyrosine kinase inhibitor crizotinib in ROS1-translocated lung cancer. J Thorac Oncol 7:1086-1090, 2012
20. Bos M, Gardizi M, Schildhaus HU, et al: Complete metabolic response in a patient with repeatedly relapsed non-small cell lung cancer harboring ROS1 gene rearrangement after treatment with crizotinib. Lung Cancer 81:142-143, 2013
21. Awad MM, Katayama R, McTigue M, et al: Acquired resistance to crizotinib from a mutation in CD74-ROS1. N Engl J Med 368:2395-2401, 2013
22. Chiari R, Buttitta F, Iacono D, et al: Dramatic response to crizotinib in ROS1 fluorescent in situ hybridization- and immunohistochemistry-positive lung adenocarcinoma: A case series. Clin Lung Cancer 15:470-474, 2014
23. Li H, Pan Y, Wang R, et al: Response to crizotinib observed in metastatic mediastinum lymph node from a non-small cell lung cancer patient harboring EZR-ROS1 fusion. J Cancer Res Clin Oncol 141:185-187, 2015
24. Shaw AT, Ou SH, Bang YJ, et al: Crizotinib in ROS1-rearranged non-smallcell lung cancer. N Engl J Med 371:1963-1971, 2014
25. Chabner BA: Early accelerated approval for highly targeted cancer drugs. N Engl J Med 364:1087-1089, 2011
26. Sharma MR, Schilsky RL: Role of randomized phase III trials in an era of effective targeted therapies. Nat Rev Clin Oncol 9:208-214, 2012
27. Gaddipati H, Liu K, Pariser A, et al: Rare cancer trial design: Lessons from FDA approvals. Clin Cancer Res 18:5172-5178, 2012
28. Tsimberidou AM, Braiteh F, Stewart DJ, et al: Ultimate fate of oncology drugs approved by the US Food and Drug Administration without a randomized trial. J Clin Oncol 27:6243-6250, 2009
29. Lipson D, Capelletti M, Yelensky R, et al: Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. Nat Med 18:382-384, 2012
30. Vaishnavi A, Capelletti M, Le AT, et al: Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer. Nat Med 19:1469-1472, 2013
31. Fernandez-Cuesta L, Plenker D, Osada H, et al: CD74-NRG1 fusions in lung adenocarcinoma. Cancer Discov 4:415-422, 2014
32. Wang R, Wang L, Li Y, et al: FGFR1/3 tyrosine kinase fusions define a unique molecular subtype of non-small cell lung cancer. Clin Cancer Res 20:4107-4114, 2014
33. Capelletti M, Dodge ME, Ercan D, et al: Identification of recurrent FGFR3-TACC3 fusion oncogenes from lung adenocarcinoma. Clin Cancer Res 20:6551-6558, 2014
34. Kris MG, Johnson BE, Berry LD, et al: Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA 311:1998-2006, 2014
35. Nowak F, Calvo F, Soria JC: Europe does it better: Molecular testing across a national health care system-The French example. Am Soc Clin Oncol Educ Book 2013:332-337, 2013